[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534159":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":42,"locations":48,"responsibleParty":157,"collaborators":159,"id":168,"slug":169,"hasResults":170,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":28,"eligibilityCriteria":174,"healthyVolunteers":170,"sex":175,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":28,"studyType":181,"phases":182,"briefSummary":184,"conditions":185,"keywords":28,"overallStatus":51,"whyStopped":28,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"The control group","ACTIVE_COMPARATOR","Endoscopic surgery + adjuvant therapy",[13,14],"Procedure: endoscopic surgery","Drug: Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"The experimental group","EXPERIMENTAL","Neoadjuvant therapy +endoscopic surgery + adjuvant therapy",[13,20,21],"Drug: Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy","Drug: Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy",[23,29,34,38],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","endoscopic surgery","The tumor was resected by endoscopic nasopharyngectomy.",[9,16],null,{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":28},"DRUG","Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy","Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.",[16],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy","Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.",[16],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":28},"Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy","Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.",[9],[43],{"name":44,"role":45,"phone":46,"phoneExt":28,"email":47},"Xiaole Song","CONTACT","+8621 64377134","jxfxsxl@163.com",[49,75,90,104,119,130,143],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Eye& ENT Hospital, Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200031","China","CN",{"type":58,"coordinates":59},"Point",[60,61],121.45806,31.22222,{"lat":61,"lon":60},[64,66,69,71,73],{"name":44,"role":45,"phone":65,"phoneExt":28,"email":47},"15821388769",{"name":67,"role":68,"phone":28,"phoneExt":28,"email":28},"Hongmeng Yu","PRINCIPAL_INVESTIGATOR",{"name":44,"role":70,"phone":28,"phoneExt":28,"email":28},"SUB_INVESTIGATOR",{"name":72,"role":70,"phone":28,"phoneExt":28,"email":28},"Li Yan",{"name":74,"role":70,"phone":28,"phoneExt":28,"email":28},"Yuting Lai",{"facility":76,"status":77,"city":78,"state":28,"zip":28,"country":55,"countryCode":56,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Fujian Medical University Union Hospital","NOT_YET_RECRUITING","Fuzhou",{"type":58,"coordinates":80},[81,82],119.30611,26.06139,{"lat":82,"lon":81},[85,87,88],{"name":86,"role":45,"phone":28,"phoneExt":28,"email":28},"Desheng Wang",{"name":86,"role":68,"phone":28,"phoneExt":28,"email":28},{"name":89,"role":70,"phone":28,"phoneExt":28,"email":28},"Haichun Lai",{"facility":91,"status":51,"city":92,"state":28,"zip":28,"country":55,"countryCode":56,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"The People's Hospital of Guangxi Zhuang Autonomous Region","Nanning",{"type":58,"coordinates":94},[95,96],108.31667,22.81667,{"lat":96,"lon":95},[99,101,102],{"name":100,"role":45,"phone":28,"phoneExt":28,"email":28},"Shenhong Qu",{"name":100,"role":68,"phone":28,"phoneExt":28,"email":28},{"name":103,"role":70,"phone":28,"phoneExt":28,"email":28},"Jingjin Weng",{"facility":105,"status":77,"city":52,"state":28,"zip":28,"country":55,"countryCode":56,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"Changhai Hospital",{"type":58,"coordinates":107},[60,61],{"lat":61,"lon":60},[110,112,113,115,117],{"name":111,"role":45,"phone":28,"phoneExt":28,"email":28},"Haihong Tang",{"name":111,"role":68,"phone":28,"phoneExt":28,"email":28},{"name":114,"role":70,"phone":28,"phoneExt":28,"email":28},"Hongliang Zheng",{"name":116,"role":70,"phone":28,"phoneExt":28,"email":28},"Haopu Li",{"name":118,"role":70,"phone":28,"phoneExt":28,"email":28},"Fengya Pan",{"facility":120,"status":77,"city":52,"state":28,"zip":28,"country":55,"countryCode":56,"cosmosGeoPoint":121,"geoPoint":123,"contacts":124},"Shanghai Sixth People's Hospital",{"type":58,"coordinates":122},[60,61],{"lat":61,"lon":60},[125,127,128],{"name":126,"role":45,"phone":28,"phoneExt":28,"email":28},"Weitian Zhang",{"name":126,"role":68,"phone":28,"phoneExt":28,"email":28},{"name":129,"role":70,"phone":28,"phoneExt":28,"email":28},"Ru Tang",{"facility":131,"status":77,"city":52,"state":28,"zip":28,"country":55,"countryCode":56,"cosmosGeoPoint":132,"geoPoint":134,"contacts":135},"Shanghai Zhongshan Hospital",{"type":58,"coordinates":133},[60,61],{"lat":61,"lon":60},[136,138,139,141],{"name":137,"role":45,"phone":28,"phoneExt":28,"email":28},"Xinsheng Huang",{"name":137,"role":68,"phone":28,"phoneExt":28,"email":28},{"name":140,"role":68,"phone":28,"phoneExt":28,"email":28},"Xianhui Ning",{"name":142,"role":68,"phone":28,"phoneExt":28,"email":28},"Lei Zhou",{"facility":144,"status":77,"city":145,"state":28,"zip":28,"country":55,"countryCode":56,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"Shenzhen Second People's Hospital","Shenzhen",{"type":58,"coordinates":147},[148,149],114.0683,22.54554,{"lat":149,"lon":148},[152,154,155],{"name":153,"role":45,"phone":28,"phoneExt":28,"email":28},"Yongtian Lu",{"name":153,"role":68,"phone":28,"phoneExt":28,"email":28},{"name":156,"role":68,"phone":28,"phoneExt":28,"email":28},"Jing Tao",{"type":158,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[160,161,163,164,165,167],{"name":131,"class":6},{"name":162,"class":6},"Shanghai 6th People's Hospital",{"name":105,"class":6},{"name":76,"class":6},{"name":166,"class":6},"People's Hospital of Guangxi Zhuang Autonomous Region",{"name":144,"class":6},"100534159","phase-3-neoadjuvant-vs-adjuvant-in-locally-advanced-recurrent-npc-100534159",false,"NCT06235203","Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC","Neoadjuvant-Adjuvant Versus Adjuvant-Only Therapy Combined With Endoscopic Surgery in Advanced Recurrent Nasopharyngeal Carcinoma:A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologically diagnosed with recurrent nasopharyngeal carcinoma;\n2. Resectable disease staging rT2 (deep parapharyngeal space, or distance to the internal carotid ≤5mm) or rT3 (excluding the lesions confined to the basal wall of sphenoid sinus), rT4, according to AJCC 8th edition;\n3. Cervical lymph node metastasis can be controlled locally;\n4. Aged 18 to 75 years;\n5. Informed consent forms signed to participate in the trial;\n6. Without distant metastasis;\n7. ≥6months from the accomplishment of radical radiation to recurrence\n8. previously only 1 course of radiotherapy;\n9. Sufficient organ function;\n10. ECOG score 0-2 and can tolerate surgery,chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Participate in other interventional clinical trials;\n2. Uncontrolled illnesses that interfere with the therapy;\n3. Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ, etc.);\n4. Any contradiction to surgery;\n5. With serious autoimmune disease;\n6. The patient is currently using immunosuppressive agents or systemic hormone therapy to achieve immunosuppressive effects (dosage\\>10mg\u002Fday prednisone or other glucocorticoids), and continues to use them within 2 weeks before the first administration;\n7. Severe allergic reactions to other monoclonal antibodies;\n8. History of radioactive particle planting;\n9. Vaccination with live vaccine within 4 weeks prior to initial administration or possibly during the study period;\n10. Female patients who are at pregnancy or lactation;\n11. Other situations that the researchers believe not suitable for enrollment","ALL","18 Years","75 Years",{"count":179,"type":180},154,"ESTIMATED","INTERVENTIONAL",[183],"PHASE3","A multicenter randomized controlled study of surgery combined with neoadjuvant and adjuvant therapy for locally advanced recurrent nasopharyngeal carcinoma in comparison to surgery combined with adjuvant therapy",[186],"Recurrent Nasopharyngeal Carcinoma","2025-05-28",{"date":189,"type":190},"2025-06-03","ACTUAL",{"date":192,"type":190},"2024-07-09",{"date":194,"type":180},"2027-06-30",{"name":5,"class":6},7]